Last reviewed · How we verify
SS109
At a glance
| Generic name | SS109 |
|---|---|
| Sponsor | Jiangsu Gensciences lnc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment (PHASE1, PHASE2)
- A Phase I of SS109 in Hemophilia A or and B With Inhibitors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SS109 CI brief — competitive landscape report
- SS109 updates RSS · CI watch RSS
- Jiangsu Gensciences lnc. portfolio CI